Press Release Archive
-
XARELTO® (rivaroxaban) Associated with Significantly Reduced Time in Hospital and Decreased Costs Compared to Standard of Care in New Study of Patients with Low-Risk Pulmonary Embolism (PE)
-
Johnson & Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc.
-
New Late-Breaking Data on the Use of Type 2 Diabetes Treatment INVOKANA® (canagliflozin) in the Real World Will Be Presented at the American Diabetes Association’s 78th Annual Scientific Sessions
-
DePuy Synthes Launches Innovative Nailing System Aimed at Improving Treatment of Femoral Shaft Fractures in the U.S.
-
Johnson & Johnson Announces Binding Offer from Fortive Corporation to Acquire Advanced Sterilization Products (ASP)
-
Johnson & Johnson Announces Progress Toward Health for Humanity GoalsAnnual Health for Humanity Report Discloses Progress on Global Commitments and Highlights Key Achievements Toward Eradicating and Preventing Disease, Reimagining Care Delivery and Promoting Lifelong Health
-
James Allison, Ph.D., Wins 2018 Dr. Paul Janssen Award for Biomedical Research
-
Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer
-
IMBRUVICA® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström’s Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin’s Lymphoma
-
Long-Term Phase 3 Study Shows Esketamine Nasal Spray Plus an Oral Antidepressant Delayed Time to Relapse in Patients with Treatment-Resistant Depression